Tarsus Pharmaceuticals, Inc. (TARS)
NMS – Real Time Price. Currency in USD
69.85
+0.39 (0.55%)
Market open: Aug 12, 2026, 11:12 AM EDT
70.00
+0.54 (0.78%)
Previous after-hours: Aug 11, 2026, 7:43 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
69.85
+0.39 (0.55%)
Market open: Aug 12, 2026, 11:12 AM EDT
70.00
+0.54 (0.78%)
Previous after-hours: Aug 11, 2026, 7:43 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $204.6M significantly exceed its total debt $88.7M, ensuring strong financial flexibility
Total current assets $562.0M exceed Total current liabilities $175.8M, highlighting excellent liquidity
Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-9.2x) is dangerously low, suggesting debt repayment risks
The company generates positive free cash flow $57.2M, supporting its financial health
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.20 | 6.05 | 10 | |
| Quick ratio | 3.17 | 5.63 | 10 | |
| Debt to Equity | 0.26 | 0.30 | 8.0 | |
| Debt to Assets | 0.15 | 1.04 | 8.0 | |
| Interest coverage | -9.23 | -16.91 | 1.0 | |
| Weighted average score | 7.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 26M | 17M | 183M | 451M | 606M |
| Gross Profit | 25M | 16M | 170M | 421M | 566M |
| Operating Income | -63M | -143M | -121M | -71M | -49M |
| Net Income | -62M | -136M | -116M | -66M | -46M |
| EBITDA | -62M | -142M | -119M | -69M | -46M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 51.64 | -423.77 | 5.5 |
| Next quarter | 31.1 | 134.12 | 10 |
| Current year | 57.82 | -24.8 | 5.5 |
| Next year | 28.9 | 212.05 | 10 |
| Weighted average score | 7.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 7.32 | -166.26 | -168.74 | 287.57 | 4.3 |
| Y/Y | 69.41 | 8.8 | 10.42 | 288.08 | 8.3 |
| 3y average | 354.31 | -20.44 | -0.51 | -12.55 | 3.3 |
| 5y average | 401.44 | -72.39 | -38.63 | -317.91 | 3.3 |
| Weighted average score | 4.8 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |